Basic Information
| Drug ID | DDPD08864 |
|
| Drug Name | Rilpivirine | |
| Molecular Weight | 366.4185 | |
| Molecular Formula | C22H18N6 | |
| CAS Number | 500287-72-9 | |
| SMILES | CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C=C2)C#N)=N1 | |
| External Links | ||
| DRUGBANK | DB08864 | |
| PubChem Compound | 6451164 | |
| PDR | 1449 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 4.86 | - | 4.86 | - | Usach, et al. J Int AIDS Soc. 16(1): 18567. (2013) |
| Melting Point | 242.0 | ℃ | 241-243 | ℃ | Sun, et al.: J. Med. Chem., 41, 4648 (1998) Kashiwada, et al.: Bioorg. Med. Chem. Lett., 11, 183 (2001) |
| Water Solubility | 100.0 | mg/L | <0.1 | mg/ml | Usach, et al. J Int AIDS Soc. 161): 18567. 2013) |
| pKa | 5.6 | - | 5.6 | - | Usach, et al. J Int AIDS Soc. 16(1): 18567. (2013) |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Reference |
|---|---|---|---|---|---|---|
| AUC | 2235.0 | ng.h/ml | 2235.0 | ng.h/ml | PO, oral; | DRUGBANK |
| T Max | 3.5 | h | 3-4 | h | PO, oral; | DRUGBANK |
| Clearance | 11.2 | L/h | 10.5-11.8 | L/h | apparent clearance; PO, oral; | DRUGBANK |
| Volume of Distribution | 162.5 | L | 152-173 | L | Apparent volume of distribution; AIDS,HIV; patients; | DRUGBANK |
| Half-life | 44.5 | h | 34-55 | h | PO, oral; | DRUGBANK |
| Eliminate Route | 85.0 | % | 85 | % | Faeces excretion; | DRUGBANK | Eliminate Route | 6.0 | % | 6 | % | Urinary excretion; | DRUGBANK | Eliminate Route | 25.0 | % | 25 | % | Faeces excretion; Unchanged drug; | DRUGBANK | Eliminate Route | 1.0 | % | <1 | % | Urinary excretion; Unchanged drug; | DRUGBANK |
| Protein Binding | 99.0 | % | >99 | % | plasma proteins; | DRUGBANK |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 25.0 | mg/day | 25 | mg/day | PO, oral | Edurant | rilpivirine | PDR |
| Max dose for children | 50.0 | mg/day | 50 | mg/day | PO, oral | Edurant | rilpivirine | PDR |
| Max dose for adolescents | 25.0 | mg/day | 25 | mg/day | PO, oral | Edurant | rilpivirine | PDR |
| Max dose for adolescents | 50.0 | mg/day | 50 | mg/day | PO, oral | Edurant | rilpivirine | PDR |
| Max dose for adults | 25.0 | mg/day | 25 | mg/day | PO, oral | Edurant | rilpivirine | PDR |
| Max dose for adults | 50.0 | mg/day | 50 | mg/day | PO, oral | Edurant | rilpivirine | PDR |
| Max dose for geriatric | 25.0 | mg/day | 25 | mg/day | PO, oral | Edurant | rilpivirine | PDR |
| Max dose for geriatric | 50.0 | mg/day | 50 | mg/day | PO, oral | Edurant | rilpivirine | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1